The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
Saya L JacobAndrew A DavisLorenzo GerratanaMarko VelimirovicAmi N ShahFiras WehbeNeelima KatamQiang ZhangLisa FlaumKalliopi P SiziopikouLeonidas C PlataniasWilliam J GradisharAmir BehdadAditya BardiaMassimo CristofanilliPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Serial ctDNA testing identified resistance alterations and increased NOA and MAF were associated with disease progression. Prospective longitudinal ctDNA evaluation could potentially monitor tumor genomic evolution.